Alcohol withdrawal drives depressive behaviors by activating neurons in the rostromedial tegmental nucleus

Neuropsychopharmacology. 2019 Jul;44(8):1464-1475. doi: 10.1038/s41386-019-0378-8. Epub 2019 Mar 31.

Abstract

Rostromedial tegmental nucleus (RMTg) GABA neurons exert a primary inhibitory drive onto midbrain dopamine neurons and are excited by a variety of aversive stimuli. There is, however, little evidence that the RMTg-ventral tegmental area (VTA)-nucleus accumbens shell (Acb) circuit plays a role in the aversive consequences of alcohol withdrawal. This study was performed in adult male Long-Evans rats at 48-h withdrawal from chronic alcohol drinking in the intermittent schedule. These rats displayed clear anhedonia and depression-like behaviors, as measured with the sucrose preference, and forced swimming tests. These aberrant behaviors were accompanied by a substantial increase in cFos expression in the VTA-projecting RMTg neurons, identified by a combination of immunohistochemistry and retrograde-tracing techniques. Pharmacological or chemogenetic inhibition of RMTg neurons mitigated the anhedonia and depression-like behaviors. Ex vivo electrophysiological data showed that chemogenetic inactivation of RMTg neurons reduced GABA release and accelerated spontaneous firings of VTA dopamine neurons. Finally, using a functional hemispheric disconnection procedure, we demonstrated that inhibition of unilateral RMTg, when combined with activation of D1 and D2 dopamine receptors in the contralateral (but not ipsilateral) Acb, mitigated the anhedonia and depression-like behaviors in alcohol-withdrawal rats. These data show that the integrity in the RMTg-VTA-Acb pathway in a single hemisphere is sufficient to elicit depression-like behavior during ethanol-withdrawal. Overall, the present results reveal that the RMTg-VTA-Acb pathway plays a crucial role in the depression-like behavior in animals undergoing alcohol withdrawal, further advocating the RMTg as a potential therapeutic target for alcoholism.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • 2-Amino-5-phosphonovalerate / pharmacology
  • Animals
  • Behavior, Animal / physiology
  • Clozapine / analogs & derivatives
  • Clozapine / pharmacology
  • Dopaminergic Neurons / physiology
  • Ethanol / adverse effects
  • Male
  • Microinjections
  • Neural Inhibition / physiology
  • Neural Pathways / physiology
  • Nucleus Accumbens / drug effects
  • Nucleus Accumbens / physiology
  • Proto-Oncogene Proteins c-fos / metabolism
  • Quinoxalines / pharmacology
  • Quinpirole
  • Rats
  • Substance Withdrawal Syndrome / physiopathology*
  • Substance Withdrawal Syndrome / psychology*
  • Tegmentum Mesencephali / drug effects
  • Tegmentum Mesencephali / metabolism
  • Tegmentum Mesencephali / physiology*
  • Ventral Tegmental Area / metabolism
  • Ventral Tegmental Area / physiology*
  • gamma-Aminobutyric Acid / metabolism

Substances

  • Proto-Oncogene Proteins c-fos
  • Quinoxalines
  • Quinpirole
  • Ethanol
  • gamma-Aminobutyric Acid
  • FG 9041
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • 2-Amino-5-phosphonovalerate
  • Clozapine
  • clozapine N-oxide